Nurix Therapeutics
Quarterly Financials
| Values in thousands | 2024-08-31 | 2024-05-31 | 2024-02-29 | 2023-11-30 |
|---|---|---|---|---|
Revenue | $12,588 | $12,092 | $16,585 | $15,159 |
Gross Profit | 8,442 | 8,001 | 12,697 | 11,402 |
EBITDA | -54,611 | -44,449 | -41,331 | -41,577 |
EBIT | -58,757 | -48,540 | -45,219 | -45,334 |
Net Income | -48,956 | -44,546 | -41,518 | -41,956 |
Net Change In Cash | 12,588 | 12,092 | 16,585 | 15,159 |
Free Cash Flow | -44,524 | -41,642 | -44,835 | 19,164 |
Cash | 99,044 | 116,790 | 49,813 | 54,627 |
Basic Shares | 72,779 | 62,377 | 54,903 | 54,670 |
Annual Financials
| Values in thousands | 2023-11-30 | 2022-11-30 | 2021-11-30 | 2020-11-30 |
|---|---|---|---|---|
Revenue | $76,987 | $38,627 | $29,750 | $17,820 |
Gross Profit | 63,333 | 38,627 | 29,750 | 17,820 |
EBITDA | -141,409 | -173,059 | -111,804 | -62,803 |
EBIT | -155,063 | -183,867 | -117,886 | -64,983 |
Net Income | -143,948 | -166,045 | -117,194 | -43,242 |
Net Change In Cash | 76,987 | 38,627 | 29,750 | 17,820 |
Cost of Revenue | -15,417 | -38,734 | 84,540 | |
Free Cash Flow | -89,766 | -172,051 | -90,026 | -4,633 |
Cash | 54,627 | 64,474 | 80,506 | 119,356 |
Basic Shares | 54,337 | 48,607 | 42,895 | 15,673 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-08-31 | -$0.67 |
2024-05-31 | -$0.71 |
2024-02-29 | -$0.76 |
2023-11-30 | -$0.77 |
